Medpace (MEDP)
(Delayed Data from NSDQ)
$390.91 USD
+4.59 (1.19%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $390.50 -0.41 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$390.91 USD
+4.59 (1.19%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $390.50 -0.41 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Zacks News
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
by Zacks Equity Research
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
by Zacks Equity Research
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay
by Zacks Equity Research
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
by Zacks Equity Research
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
Charles River (CRL) Launches Viral Vector Tech Transfer Program
by Zacks Equity Research
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
QIAGEN (QGEN) Develops Test for Research and CDx Application
by Zacks Equity Research
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success
by Zacks Equity Research
Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.
SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon
by Zacks Equity Research
SenesTech (SNES) looks to leverage the convenience and reach of e-commerce to expand its market share.
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
by Zacks Equity Research
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
Reasons to Hold Charles River (CRL) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Here is Why Growth Investors Should Buy Medpace (MEDP) Now
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant
by Zacks Equity Research
Inspira Technologies' (IINN) ART100 recent approval highlights the company's innovative advancements in medical technology.
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
by Zacks Equity Research
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
Medpace (MEDP) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Medpace (MEDP) settling at $390.81, representing a +0.07% change from its previous close.
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
by Zacks Equity Research
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
Here's Why Investors Should Retain ICON (ICLR) Stock Now
by Zacks Equity Research
Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.
Stereotaxis (STXS) Gets CE Recertification for Approved Products
by Zacks Equity Research
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.
Charles River (CRL) Banks on RMS Growth Amid Competition
by Zacks Equity Research
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
Here's Why You Should Retain Edward Lifesciences (EW) for Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.
Zacks Market Edge Highlights: Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco
by Zacks Equity Research
Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco are part of the Zacks Market Edge blog.
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
by Zacks Equity Research
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Reasons to Include Alcon (ALC) in Your Portfolio Right Now
by Zacks Equity Research
New product launches and strong solvency bode well for Alcon (ALC).